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Chronic myelogenous leukemia (CML) is a myeloproliferative disorder that normally presents in middle-
aged adults. Renal inﬁltration and extramedullary hematopoiesis in renal tissue has been rarely reported.
This case report presents a patient with CML and renal insufﬁciency who developed gross hematuria.
Efforts at controlling the hematuria led to a cascade of events propelled by the underlying disorder that
ultimately led to a radical nephrectomy, multiorgan failure, and prolonged hospitalization. We suggest
that management of gross hematuria in clinically stable patients with CML, suspected of having extra-
medullary hematopoiesis, should prioritize treatment of the myeloproliferative disorder over efforts to
control bleeding.
 2014 The Authors. Published by Elsevier Inc. All rights reserved.Introduction
Chronic myelogenous leukemia (CML) is a myeloproliferative
triphasic disorder characterized by the hyperplasia of fairly differ-
entiated granulocytic cells that normally presents in middle-aged
adults. Clinical manifestations of CML common to all phases of
the disorder include abnormal routine blood tests, constitutional
symptoms of fatigue and weight loss, abdominal pain, and
abnormal bleeding episodes. CML has variable clinical pre-
sentations and prognosis depending on disease phase and time of
diagnosis.1 Renal involvement and extramedullary hematopoiesis
associated with CML are rare but have been reported.2-4
Case presentation
A 53-year-old African-American man with a history of peptic
ulcer disease, anxiety, renal insufﬁciency (baseline creatinine level,
1.7 mg/dL) was admitted for gross hematuria and left ﬂank pain. He
works as amechanic, ismarried, andwas a former smoker.His family
history is signiﬁcant for prostate cancer and high blood pressure. He
was recently diagnosed with CML during an admission for weight
loss, easy bruising, and fatigue. A bone marrow biopsy showed hy-
perplastic granulocytes with a maturation pattern consistent with
CML. Further genetic analysis showed cells with a translocationBY-NC-SA license (http://
ettner).
Published by Elsevier Inc. All righbetween chromosomes 9 and 22, the genetic hallmark of CML. The
cellswere also positive for the genetic product of the translocation, a
defective or deregulated tyrosine kinase, also known as the BCR-ABL
protein, which is essential to the pathogenesis of the disorder. Dur-
ing that admission, he developed hematuria and bloody stools. A
computed tomography scan of his abdomen and pelvis showedmild
left hydronephrosis without obvious mass or stone, and his hema-
turia resolved. His gastrointestinal bleeding work-up included
an esophagogastroduodenoscopy and colonoscopy. Several poly-
pectomies resulted inprolongedbleeding,whichultimately resolved.
Before deﬁnitive treatment for his CML could be started, he
again developed hematuria with mild left ﬂank pain. Upper tract
imaging was negative for an overt renal mass, and a cystoscopy
found gross blood from the left ureteral oriﬁce (Fig.1). Ureteroscopy
was performed, but no obvious cause of bleeding was found.
Cytology showed left renal pelvis urine abundant in acute and
chronic inﬂammatory cells with no evidence of malignancy.
Because of persistent bleeding without a treatable source, the
patient was sent to interventional radiology for an angiography ex-
amination. A pseudoaneurysmwas noted in the left renal artery at a
small branch in the lower pole, and it was subsequently embolized
(Fig. 2). The patient’s bleeding stopped and his hematocrit remained
stable until 2 days later when he became hypotensive because of
sudden blood volume loss. He required vasopressors and intensive
care admission. A repeat arteriogram revealed a site of bleeding into
the retroperitoneum remote from the initial embolization (Fig. 3A).
The patient continued to have hemodynamic instability and
continued blood loss (Fig. 3B). Ultimately, he was taken for an
emergent left nephrectomy (Fig. 4).ts reserved.
Figure 1. Computed tomography scan (October 11, 2013) showing ﬂuid in the left
collecting system with no obvious mass or stone.
Figure 2. Angiogram (October 11, 2013) showing a pseudoaneurysm in the left renal
artery at a small branch in the lower pole. It was subsequently embolized through
interventional radiology.
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CML inﬁltration with diffuse extramedullary hematopoiesis.
Postoperatively, the patient required prolonged respiratory
support and hemodialysis. Hydroxyurea and colchicine were initi-
ated to control the patient’s leukocytosis and tumor lysis syndrome.
He experienced 2 episodes of cardiac arrest and required prolonged
vasopressor support. He was started on imatinib, a tyrosine kinase
inhibitor, which has been shown to be an effective targeted therapy
for CML. Fortunately, his condition improved and hewas discharged
on hospital day 71 on hemodialysis.
Discussion
Our patient presented with documented CML and gross hema-
turia of unknown source. The initial differential included inﬁltra-
tion of CML, urinary malignancy, infection, and nephritis. A reviewFigure 3. (A) Angiography (October 13, 2013) and second interventional radiology (IR) emb
renal artery and interlobular artery using multiple 3-mm coils. The patient continued to
retroperitoneal hematoma emerging from the left kidney.of the literature allowed us to have the foresight to put CML inﬁl-
tration high on our differential for the source of the spontaneous
bleed. Although rare, a CML inﬁltrated kidney has been reported by
Hyams et al2 to present exactly like our patient. In their 2009 case
report, their patient diagnosed with a myelomonocytic variant of
CML, presented with spontaneous gross hematuria that cleared and
then reappeared with no major ﬁndings on cystoureteroscopy,
much like our patient. Their patient also carried the necessity of
nephrectomy owing to continued bleed. Pathology showed CML
inﬁltrate and extramedullary hematopoiesis of the removed kidney,
also much like our patient.
Important to the clinical case was the patient’s hemodynamic
stability despite the gross hematuria. His kidney clearly did not
respond well to embolization. It is highly possible that the CML
inﬁltration made the kidney less likely to deal with postinfarction
changes within the kidney and made it more susceptible to a majorolization. A second IR embolization was performed on the anterior segment of the left
bleed. (B). Computed tomography scan (October 13, 2013) showing an increase in
Figure 4. Computed tomography scan (October 15, 2013) showing continued blood
loss. An emergent nephrectomy had to be performed.
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underlying CML as the best course to prevent spontaneous bleeds in
CML patients.2,5 CML has been associated with both disseminated
intravascular coagulation and defects in thrombopoiesis that may
leave patients vulnerable to bleeding, despite a normal interna-
tional normalized ratio, prothrombin time, and partial thrombo-
plastin time.2,5 Our patient continued to experience bleeding
complications postoperatively, and it is our belief that he may havefared better if he had been able to start chemotherapy before
instrumentation during cystoureteroscopy and subsequent inter-
ventional radiology procedures. These small interventions may
have precipitated further bleeding events because of exacerbation
of underlying coagulopathy related to intrinsic platelet
dysfunction.2
Conclusion
In retrospect, as soon as urethrothelial malignancywas ruled out
as the cause of hematuria in this patient, it is possible that deﬁnitive
treatment for his underlying CML should have superseded our
desire to stop his otherwise asymptomatic left renal bleeding.
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